CD22 and cancer: More recent exploration of the cancer engulfment hypothesis has uncovered additional pathways including calreticulin, CD22, and CD24 that intersect with or run parallel to the SIRPα-CD47 pathway and are also potential targets in cancer (Barkal et al., 2019; Kamber et al., 2021; Pluvinage et al., 2019).